Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3883627 | 0.90 | CCR3 (0.42) | GRM5MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL3884741 | 0.86 | KMT2A (0.43) | GRM5MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL3888022 | 0.78 | KCNH2 (0.51) | KMT2AALDH1A1MAPT | |
| SCHEMBL4126667 | 0.78 | CHRM2 (0.44) | MEN1KMT2AALDH1A1MAPTPDK2 | |
| SCHEMBL48051 | 0.76 | KMT2A (0.47) | MEN1KMT2AMAPK1 | |
| SCHEMBL3891807 | 0.73 | KMT2A (0.47) | KMT2AMAPK1 | |
| SCHEMBL48033 | 0.71 | MTNR1A (0.46) | POLBALDH1A1 | |
| SCHEMBL48100 | 0.71 | MTNR1A (0.46) | POLBALDH1A1 | |
| SCHEMBL3885528 | 0.71 | POLB (0.57) | GRM5MEN1KMT2APOLBMAPT | |
| SCHEMBL14223371 | 0.71 | NPC1 (0.55) | MEN1KMT2APOLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | GRM5 763/4885MEN1 1450/4885KMT2A 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.